Search Result
Results for "
ACE+Inhibitors
" in MedChemExpress (MCE) Product Catalog:
30
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B0279
-
-
-
- HY-B0331
-
-
-
- HY-B0592
-
|
RU44570
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
|
-
-
- HY-B0331A
-
-
-
- HY-B0477
-
-
-
- HY-B0382
-
-
-
- HY-B0231
-
|
MK-422
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Enalaprilat dihydrate (MK-422), the active metabolite of the oral proagent Enalapril, is a potent, competitive and long-acting angiotensin-converting enzyme (ACE) inhibitor, with an IC50 of 1.94 nM. Enalaprilat dihydrate can be used for the research of hypertension .
|
-
-
- HY-105858
-
-
-
- HY-B0231A
-
|
MK-422 anhydrous
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Enalaprilat (MK-422 anhydrous), the active metabolite of the oral proagent Enalapril, is a potent, competitive and long-acting angiotensin-converting enzyme (ACE) inhibitor, with an IC50 of 1.94 nM. Enalaprilat can be used for the research of hypertension .
|
-
-
- HY-B1433
-
-
-
- HY-N0214
-
-
-
- HY-B0331AR
-
-
-
- HY-B0384
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Temocapril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .
|
-
-
- HY-107352
-
-
-
- HY-B0331AS
-
-
-
- HY-107318
-
-
-
- HY-109592
-
-
-
- HY-N8630
-
-
-
- HY-100713
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Temocapril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .
|
-
-
- HY-107337
-
-
-
- HY-B0279S
-
-
-
- HY-P3985
-
|
Bradykinin potentiating peptide B
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
Others
|
|
Bradykinin potentiator B (Bradykinin potentiating peptide B) is venom of Agkistrodon halys blomhoffi. Bradykinin potentiator B is a potent ACE inhibitor. Bradykinin potentiator inhibits the activity of bradykinin inhibitory peptidase .
|
-
-
- HY-A0116A
-
|
Trandolaprilat hydrate; RU 44403 hydrate
|
Angiotensin-converting Enzyme (ACE)
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Trandolaprilate hydrate is a potent angiotensin-converting enzyme (ACE) inhibitor. Trandolaprilate hydrate partially inhibits angiotensin-I-mediated c-fos induction. Trandolaprilate is main bioactive metabolite of Trandolapril. Trandolaprilate shows high lipophilicity .
|
-
-
- HY-108321
-
-
-
- HY-B0279S1
-
-
-
- HY-121460
-
-
-
- HY-P11300
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
YKYY, a antihypertensive peptide, is an Angiotensin I-converting enzyme (ACE) inhibitor with an IC50 of 64.2 μM. YKYY can be isolated for the peptic digest of wakame Undaria pinnatifida. YKYY can be used for hypertension research .
|
-
-
- HY-P11300A
-
-
-
- HY-U00041
-
-
-
- HY-106446
-
-
-
- HY-106816
-
-
-
- HY-P3991
-
-
-
- HY-A0116
-
-
-
- HY-P4257
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
L-Isoleucyl-L-arginine is a dipeptide formed from L-isoleucine and L-arginine residues. L-Isoleucyl-L-arginine is a potent angiotensin-converting enzyme (ACE) inhibitor. L-Isoleucyl-L-arginine can be used for research of hypertension .
|
-
-
- HY-101681
-
-
-
- HY-U00074
-
-
-
- HY-116023
-
-
-
- HY-P2366
-
-
-
- HY-P2227
-
-
-
- HY-B0231BS
-
-
-
- HY-B0331B
-
-
-
- HY-121232
-
-
-
- HY-18205
-
-
-
- HY-N3470
-
-
-
- HY-W092110
-
-
-
- HY-B0690
-
-
-
- HY-P2619
-
-
-
- HY-N0214A
-
-
-
- HY-137769
-
|
3-Mercaptoisobutyric acid
|
Drug Metabolite
|
Others
|
|
Captopril EP Impurity C is an impurity of Captopril. Captopril (SQ-14534), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) .
|
-
-
- HY-N2165R
-
-
- HY-122032
-
-
- HY-Z8381
-
-
- HY-P0143
-
-
- HY-U00074R
-
-
- HY-123657
-
-
- HY-167867
-
-
- HY-137188
-
-
- HY-A0116S
-
-
- HY-B0231AS
-
-
- HY-108321S
-
-
- HY-129714
-
|
|
Renin
|
Metabolic Disease
|
|
EMD 52297 is a Renin inhibitor, with acute hemodynamic and hormonal effects. EMD 52297 also acts as an ACE inhibitor .
|
-
- HY-113681
-
-
- HY-107337S
-
-
- HY-123227
-
-
- HY-113813
-
-
- HY-118164
-
-
- HY-101733
-
-
- HY-105266
-
-
- HY-121180
-
-
- HY-P2605
-
-
- HY-B0279R
-
-
- HY-B0279S2
-
-
- HY-106446R
-
-
- HY-B0592S
-
-
- HY-B0477R
-
|
CI-906 (Standard)
|
Reference Standards
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Quinapril (hydrochloride) (Standard) is the analytical standard of Quinapril (hydrochloride). This product is intended for research and analytical applications. Quinapril (hydrochloride) (CI-906) is a proagent that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications.
|
-
- HY-P5774
-
-
- HY-50761
-
-
- HY-107318R
-
-
- HY-B0382R
-
|
SQ28555 (Standard)
|
Reference Standards
Angiotensin-converting Enzyme (ACE)
Apoptosis
|
Cardiovascular Disease
|
|
Fosinopril (sodium) (Standard) is the analytical standard of Fosinopril (sodium). This product is intended for research and analytical applications. Fosinopril Sodium is the ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor, used for the treatment of hypertension and some types of chronic heart failure.
|
-
- HY-139801
-
|
CI-907
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
Metabolic Disease
|
|
Indolapril hydrochloride (CI-907) is an orally active nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor. Indolapril hydrochloride is highly specific in suppressing the contractile or pressor responses to Angiotensin I. Indolapril hydrochloride is a potent antihypertensive agent .
|
-
- HY-19072
-
|
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
BRL-36378 is an ACE inhibitor that inhibits angiotensin-converting enzyme activity. BRL-36378 can be used in ligand-based virtual screening to identify new leading structures for chemical optimization .
|
-
- HY-117281S
-
-
- HY-109592S
-
-
- HY-114536
-
|
NSC 104800
|
Angiotensin Receptor
|
Others
|
|
Mitolactol (NSC 104800) is an angiotensin converting enzyme (ACE) inhibitor with the activity of inhibiting ACE (IC50 of 1.4×10 M) and inhibiting the pressor response of angiotensin I when administered intravenously at 0.3 mg/kg in rats.
|
-
- HY-B0477AS1
-
-
- HY-137361
-
|
Ramipril diketopiperazine acid
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Ramiprilat diketopiperazine (Ramipril diketopiperazine acid; Impurity K) is an impurity of Ramiprilat (HY-A0115). Ramiprilat, an active metabolite of Ramipril (HY-B0279), is a potent and orally active angiotensin converting enzyme (ACE) inhibitor .
|
-
- HY-143886
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
AD011 is a dual inhibitor of cACE/NEP. AD011 is synthesized based on the previously reported C-domain selective ACE inhibitor lisinopril-tryptophan. AD011 has the potential for providing the potent antihypertensive and cardioprotective benefits .
|
-
- HY-143888
-
-
- HY-143887
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
AD012 is a dual inhibitor of cACE/NEP. AD012 is synthesized based on the previously reported C-domain selective ACE inhibitor lisinopril-tryptophan. AD012 has the potential for providing the potent antihypertensive and cardioprotective benefits .
|
-
- HY-B0331S1
-
-
- HY-A0043S2
-
-
- HY-100713S
-
-
- HY-P3424
-
-
- HY-137768
-
|
|
Drug Metabolite
|
Others
|
|
Captopril EP Impurity B is an impurity of Captopril. Captopril (SQ-14534), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) .
|
-
- HY-W013886
-
|
S-Acetylcaptopril
|
Drug Metabolite
|
Others
|
|
Captopril EP Impurity J is an impurity of Captopril. Captopril (SQ-14534), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) .
|
-
- HY-127026A
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Quinaprilat hydrate is a non-mercapto Angiotensin Converting Enzyme (ACE) inhibitor, the active metabolite of Quinapril. Quinaprilat hydrate specifically blocks the conversion of angiotensin I to the vasoconstrictor angiotensin II and inhibits the degradation of bradykinin. Quinaprilat hydrate acts as anti-hypertensive agent and vasodilator .
|
-
- HY-105261
-
-
- HY-P11572
-
-
- HY-106457
-
-
- HY-107337R
-
-
- HY-137772
-
|
|
Drug Metabolite
|
Others
|
|
Captopril EP Impurity E is an impurity of Captopril. Captopril (SQ-14534), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) .
|
-
- HY-B0130S
-
-
- HY-B0592A
-
|
RU44570 hydrochloride
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Trandolapril (RU44570) hydrochloride is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolapril hydrochlorideat. Trandolapril hydrochloride is an orally active angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
|
-
- HY-N2165
-
-
- HY-127026B
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Quinaprilat hydrochloride is an orally active non-mercapto Angiotensin Converting Enzyme (ACE) inhibitor, the active metabolite of Quinapril. Quinaprilat hydrochloride specifically blocks the conversion of angiotensin I to the vasoconstrictor angiotensin II and inhibits the degradation of bradykinin. Quinaprilat hydrochloride acts as anti-hypertensive agent and vasodilator .
|
-
- HY-B1433R
-
|
S 9780 (Standard)
|
Angiotensin-converting Enzyme (ACE)
Reference Standards
|
Cardiovascular Disease
|
|
Perindoprilat (Standard) is the analytical standard of Perindoprilat. This product is intended for research and analytical applications. Perindoprilat (S 9780) is an angiotensin-converting enzyme (ACE) inhibitor with the IC50 value ranging from 1.5 to 3.2 nM. Perindoprilat can be used in hypertension research .
|
-
- HY-127026
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Quinaprilat is an orally active non-mercapto Angiotensin Converting Enzyme (ACE) inhibitor, the active metabolite of Quinapril. Quinaprilat specifically blocks the conversion of angiotensin I to the vasoconstrictor angiotensin II and inhibits the degradation of bradykinin. Quinaprilat acts as anti-hypertensive agent and vasodilator .
|
-
- HY-W739949
-
-
- HY-A0230A
-
|
SCH 33844 hydrochloride
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Spirapril (SCH 33844) hydrochloride is a potent angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Spirapril competitively binds to ACE and prevents the conversion of angiotensin I to angiotensin II. Spirapril is an orally active proagent of Spiraprilat and can be used for the research of hypertension, congestive heart failure .
|
-
- HY-107352R
-
-
- HY-A0116S1
-
|
|
Angiotensin-converting Enzyme (ACE)
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Trandolaprilate-d6 is the deuterium labeled Trandolaprilate . Trandolaprilate is a potent angiotensin-converting enzyme (ACE) inhibitor. Trandolaprilate partially inhibits angiotensin-I-mediated c-fos induction. Trandolaprilate is main bioactive metabolite of Trandolapril. Trandolaprilate shows high lipophilicity .
|
-
- HY-B1433S
-
-
- HY-100713R
-
|
|
Reference Standards
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Temocapril (Standard) is the analytical standard of Temocapril. This product is intended for research and analytical applications. Temocapril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .
|
-
- HY-A0115S1
-
-
- HY-B0384R
-
|
|
Angiotensin-converting Enzyme (ACE)
Reference Standards
|
Cardiovascular Disease
|
|
Temocapril (hydrochloride) (Standard) is the analytical standard of Temocapril (hydrochloride). This product is intended for research and analytical applications. Temocapril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .
|
-
- HY-107339
-
-
- HY-A0043A
-
|
Ro 31-2848 monohydrate
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Cilazapril monohydrate is an orally active prodrug of the angiotensin-converting enzyme (ACE) inhibitor Cilazaprilat (HY-A0113). Cilazapril monohydrate reduces plasma ACE activity. Cilazapril monohydrate can be used in the research of hypertension (including essential and renal hypertension) and congestive heart failure .
|
-
- HY-A0043
-
|
Ro 31-2848
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Cilazapril is an orally active prodrug of the angiotensin-converting enzyme (ACE) inhibitor Cilazaprilat (HY-A0113). Cilazapril reduces plasma ACE activity. Cilazapril can be used in the research of hypertension (including essential and renal hypertension) and congestive heart failure .
|
-
- HY-A0043B
-
|
Ro 31-2848 hydrochloride
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Cilazapril hydrochloride is an orally active prodrug of the angiotensin-converting enzyme (ACE) inhibitor Cilazaprilat (HY-A0113). Cilazapril hydrochloride reduces plasma ACE activity. Cilazapril hydrochloride can be used in the research of hypertension (including essential and renal hypertension) and congestive heart failure .
|
-
- HY-A0115
-
-
- HY-A0116R
-
|
Trandolaprilat (Standard); RU 44403 (Standard)
|
Reference Standards
Angiotensin-converting Enzyme (ACE)
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Trandolaprilate (Standard) is the analytical standard of Trandolaprilate. This product is intended for research and analytical applications. Trandolaprilate is a potent angiotensin-converting enzyme (ACE) inhibitor. Trandolaprilate partially inhibits angiotensin-I-mediated c-fos induction. Trandolaprilate is main bioactive metabolite of Trandolapril. Trandolaprilate shows high lipophilicity .
|
-
- HY-182457
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
N-Mercaptoacetyl-L-histidine is an angiotensin-converting enzyme (ACE) inhibitor with a target pIC50 of 3.59 M.N-Mercaptoacetyl-L-histidine binds to the zinc-containing active site of ACE, which mediates conversion of angiotensin I to angiotensin II.N-Mercaptoacetyl-L-histidine can be used for the research of hypertension .
|
-
- HY-A0230
-
|
SCH 33844
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Spirapril is a potent and cross the blood-brain barrier angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Spirapril competitively binds to ACE and prevents the conversion of angiotensin I to angiotensin II. Spirapril is an orally active proagent of Spiraprilat and can be used for the research of hypertension, congestive heart failure .
|
-
- HY-A0115S2
-
-
- HY-Z7082
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Perindopril L-arginine is an orally active and selective angiotensin-converting enzyme (ACE) inhibitor. Perindopril L-arginine reduces the production of angiotensin II by inhibiting ACE, thereby dilating blood vessels, lowering blood pressure, and also exerting activities such as vasculoprotection and antithrombosis. Perindopril L-arginine is promising for research of cardiovascular diseases .
|
-
- HY-P11740
-
|
|
Angiotensin-converting Enzyme (ACE)
Drug Intermediate
|
Others
|
|
VYPFPGPIHN is a precursor peptide of β-casomorphin (HY-P0179) and also an ACE inhibitor (IC50 = 123 μM). VYPFPGPIHN resists hydrolysis by peptidases associated with intestinal cell monolayers, maintaining structural integrity and ACE inhibitory activity. VYPFPGPIHN is not extensively taken up or transported by differentiated intestinal cell monolayers .
|
-
- HY-B0592R
-
|
RU44570 (Standard)
|
Reference Standards
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Trandolapril (Standard) is the analytical standard of Trandolapril. This product is intended for research and analytical applications. Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
|
-
- HY-127026S
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Quinaprilat-d5 is a deuterium-labeled Quinaprilat (HY-127026). Quinaprilat is a nonsulfhydryl ACE inhibitor, the active diacid metabolite of Quinapril. Quinaprilat specifically blocks the conversion of angiotensin I to the vasoconstrictor angiotensin II and inhibits bradykinin degradation. Quinaprilat primarily acts as a vasodilator, decreasing total peripheral and renal vascular resistance .
|
-
- HY-121796
-
|
|
Neprilysin
|
Others
|
|
Mixanpril is a compound with the ability to modulate insulin sensitivity and has the activity of regulating insulin sensitivity and femoral blood flow in obese Zucker rats. Mixanpril can affect insulin-mediated glucose disposal in obese Zucker rats and also has a regulatory effect on femoral blood flow, with different effects compared to the ACE inhibitor captopril.
|
-
- HY-N0214R
-
-
- HY-P4551
-
|
N-Benzoyl-Gly-His-Leu
|
Angiotensin-converting Enzyme (ACE)
Amino Acid Derivatives
|
Cardiovascular Disease
|
|
Hippuryl-His-Leu-OH (N-Benzoyl-Gly-His-Leu) is a specific substrate for angiotensin-converting enzyme (ACE I) and a molecular tool used for ACE activity detection in in vitro experiments. Hippuryl-His-Leu-OH is hydrolyzed by ACE through competitive binding. Under ACE catalysis, Hippuryl-His-Leu-OH undergoes hydrolysis to produce hippuric acid (HA). The amount of HA produced can be used to quantitatively assess ACE activity or screen for ACE inhibitors. The released His-Leu can also react with o-phthalaldehyde or Fluorescamine (HY-D0715) for fluorescence detection. Hippuryl-His-Leu-OH can be applied to the in vitro screening of ACE inhibitors for hypertension and cardiovascular diseases, and is also used in the study of ACE activity changes in physiological and pathological processes such as renal compensatory hypertrophy .
|
-
- HY-W744298
-
|
|
Isotope-Labeled Compounds
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Trandolapril-d3 is the deuterium labeled Trandolapril (HY-B0592). Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
|
-
- HY-B0231R
-
|
MK-422 (Standard)
|
Reference Standards
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Enalaprilat (dihydrate) (Standard) is the analytical standard of Enalaprilat (dihydrate). This product is intended for research and analytical applications. Enalaprilat dihydrate (MK-422), the active metabolite of the oral proagent Enalapril, is a potent, competitive and long-acting angiotensin-converting enzyme (ACE) inhibitor, with an IC50 of 1.94 nM. Enalaprilat dihydrate can be used for the research of hypertension .
|
-
- HY-121858
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Metabolic Disease
|
|
Nicotianamine can be isolated from the leaves of Nicotiana Tabacum L.. Nicotianamine is a key biosynthetic precursor of phytosiderophores. Nicotianamine is an iron chelating agent and can promote the transport of iron. Nicotianamine is an angiotensin-converting enzyme (ACE) inhibitor with IC50 values of 76 nM and 59 nM for rhACE2 and rhACE, respectively. Nicotianamine is vital in metal nutrition and metal homeostasis of flowering plants .
|
-
- HY-B0690S
-
-
- HY-107339R
-
|
Harmonyl (Standard)
|
Reference Standards
Angiotensin-converting Enzyme (ACE)
|
Neurological Disease
Metabolic Disease
|
|
Deserpidine (Standard) is the analytical standard of Deserpidine. This product is intended for research and analytical applications. Deserpidine (Harmonyl) is an alkaloid isolated from the root of Rauwolfia canescens related to Reserpine. Deserpidine is used as an antihypertensive agent and a tranquilizer. Deserpidine is a competitive angiotensin converting enzyme (ACE) inhibitor. Deserpidine also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex .
|
-
- HY-B0655
-
|
SQ26991
|
Angiotensin-converting Enzyme (ACE)
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
|
|
Zofenopril Calcium (SQ26991) is an orally active angiotensin-converting enzyme (ACE) inhibitor with antioxidant activity and cardioprotective effects. Zofenopril Calcium reduces ROS production and GSH consumption and helps inhibit foam cell formation, thus slowing the progression of atherosclerosis. Zofenopril Calcium prevents cardiac damage caused by chronic Doxorubicin (HY-15142A) .
|
-
- HY-W585934
-
|
Fru-Phe
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Fructose-phenylalanine (Fru-Phe) is a non-competitive angiotensin-converting enzyme (ACE) inhibitor (IC50 =0.19 mM) with antioxidant activities. Fructose-phenylalanine forms a stable complex with Zn 2+ ions at the ACE active site, blocking the conversion of angiotensin I to II and thereby lowering blood pressure. Fructose-phenylalanine is promising for research of cardiovascular diseases .
|
-
- HY-P3976
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Lactalbumin B (50-53) Alpha [Lactorphin Alpha], bovine is a blood pressure lowering peptide containing 4 amino acids. Lactalbumin B (50-53) Alpha [Lactorphin Alpha], bovine is an angiotensin-converting Enzyme (ACE) inhibitor. Lactalbumin B (50-53) Alpha [Lactorphin Alpha], bovine can be used in research of high blood pressure .
|
-
![Lactalbumin B (50-53) Alpha [Lactorphin Alpha], bovine](//file.medchemexpress.com/product_pic/hy-p3976.gif)
- HY-105858R
-
|
Ile-Trp (Standard)
|
Reference Standards
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
H-Ile-Trp-OH (Standard) is the analytical standard of H-Ile-Trp-OH (HY-105858). This product is intended for research and analytical applications. H-Ile-Trp-OH (Ile-Trp), a dipeptide, is an angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 0.7 μM. H-Ile-Trp-OH inhibits predominantly the C-domain of ACE .
|
-
- HY-137875
-
|
N-Benzoyl-Gly-His-Leu hydrate
|
Angiotensin-converting Enzyme (ACE)
Amino Acid Derivatives
|
Cardiovascular Disease
|
|
Hippuryl-His-Leu-OH (N-Benzoyl-Gly-His-Leu) hydrate is a specific substrate for angiotensin-converting enzyme ACE I and is a molecular tool used for ACE activity detection in in vitro experiments. Hippuryl-His-Leu-OH hydrate is hydrolyzed by ACE through competitive binding. Under ACE catalysis, Hippuryl-His-Leu-OH hydrate undergoes hydrolysis to produce hippuric acid (HA). The amount of HA produced can be used to quantitatively assess ACE activity or screen for ACE inhibitors. The His-Leu released from Hippuryl-His-Leu-OH hydrate can also react with o-phthalaldehyde or Fluorescamine (HY-D0715) for fluorescence detection. Hippuryl-His-Leu-OH hydrate can be applied to the in vitro screening of ACE inhibitors for hypertension and cardiovascular diseases, and is also used in the study of changes in ACE activity during physiological and pathological processes such as renal compensatory hypertrophy .
|
-
- HY-127026R
-
|
|
Reference Standards
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Quinaprilat (Standard) is the analytical standard of Quinaprilat (HY-127026) . This product is intended for research and analytical applications. Quinaprilat is an orally active non-mercapto Angiotensin Converting Enzyme (ACE) inhibitor, the active metabolite of Quinapril. Quinaprilat specifically blocks the conversion of angiotensin I to the vasoconstrictor angiotensin II and inhibits the degradation of bradykinin. Quinaprilat acts as anti-hypertensive agent and vasodilator .
|
-
- HY-137772R
-
|
|
Drug Metabolite
Reference Standards
|
Others
|
|
Captopril EP Impurity E (Standard) is the analytical standard of Captopril EP Impurity E. This product is intended for research and analytical applications. Captopril EP Impurity E is an impurity of Captopril. Captopril (SQ-14534), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) .
|
-
- HY-118472
-
|
CGS 14831
|
Drug Metabolite
Endogenous Metabolite
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Benazeprilat is an orally active and the active metabolite of benazepril, a carboxyl-containing ACE inhibitor with antihypertensive activity. Benazepril is a well-established antihypertensive agent, both in monoresearch and in combination with other classes of drugs including thiazide diuretics and calcium channel blockers. Benazepril is a first-line research in reducing various pathologies associated with CV risk and secondary end-organ damage .
|
-
- HY-N4090
-
|
|
Angiotensin-converting Enzyme (ACE)
ERK
MMP
ADAMTS
p38 MAPK
|
Cardiovascular Disease
|
|
Vicenin 3 is an angiotensin-converting enzyme (ACE) inhibitor (IC50 = 46.91 μM) that can be isolated from the aerial parts of Desmodium styracifolium. Vicenin 3 ameliorates IL-1β-induced extracellular matrix degradation in SW1353 chondrocytes by regulating the MAPK pathway. Vicenin 3 can be used for the study of osteoarthritis (OA) and hypertension .
|
-
- HY-137769R
-
|
3-Mercaptoisobutyric acid (Standard)
|
Drug Metabolite
Reference Standards
|
Others
|
|
Captopril EP Impurity C (Standard) is the analytical standard of Captopril EP Impurity C. This product is intended for research and analytical applications. Captopril EP Impurity C is an impurity of Captopril. Captopril (SQ-14534), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) .
|
-
- HY-137768R
-
|
|
Drug Metabolite
Reference Standards
|
Others
|
|
Captopril EP Impurity B (Standard) is the analytical standard of Captopril EP Impurity B. This product is intended for research and analytical applications. Captopril EP Impurity B is an impurity of Captopril. Captopril (SQ-14534), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) .
|
-
- HY-B0093
-
|
CGS14824A free base
|
Angiotensin-converting Enzyme (ACE)
Apoptosis
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
Cancer
|
|
Benazepril (CGS14824A free base) is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. Benazepril improves diabetic nephropathy and decreases proteinuria. Benazepril can be used in the study of hypertension, heart failure and diabetic nephropathy .
|
-
- HY-B0592S2
-
|
rac-RU44570-d5
|
Isotope-Labeled Compounds
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
rac-Trandolapril-d5 (rac-RU44570-d5) is deuterium labeled Trandolapril. Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
|
-
- HY-B0093A
-
-
- HY-A0043R
-
|
Ro 31-2848 (Standard)
|
Reference Standards
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Cilazapril (Standard) is the analytical standard of Cilazapril (HY-A0043). This product is intended for research and analytical applications. Cilazapril is an orally active prodrug of the angiotensin-converting enzyme (ACE) inhibitor Cilazaprilat (HY-A0113). Cilazapril reduces plasma ACE activity. Cilazapril can be used in the research of hypertension (including essential and renal hypertension) and congestive heart failure .
|
-
- HY-129213
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
Others
|
|
CL-242817 is an orally available angiotensin converting enzyme (ACE) inhibitor. CL-242817 inhibits the conversion of angiotensin I to angiotensin II and has blood pressure lowering activity. CL-242817 can also improve Monocrotaline (HY-N0750) induced lung injury. CL-242817 can be used in the study of pulmonary fibrosis and hypertension-related diseases .
|
-
- HY-B0368A
-
|
SQ 14225 hydrochloride
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
Cancer
|
|
Captopril (SQ 14225) hydrochloride, antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril hydrochloride is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM .
|
-
- HY-A0043AR
-
|
Ro 31-2848 monohydrate (Standard)
|
Reference Standards
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Cilazapril (monohydrate) (Standard) is the analytical standard of Cilazapril monohydrate (HY-A0043A). This product is intended for research and analytical applications. Cilazapril monohydrate is an orally active prodrug of the angiotensin-converting enzyme (ACE) inhibitor Cilazaprilat (HY-A0113). Cilazapril monohydrate reduces plasma ACE activity. Cilazapril monohydrate can be used in the research of hypertension (including essential and renal hypertension) and congestive heart failure .
|
-
- HY-P10808
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
RSRGVFF (FOXP3 inhibitor P60) is a mixed-type angiotensin-converting enzyme (ACE) inhibitor with blood-brain barrier permeability, boasting an IC50 value of 5.01 μM . RSRGVFF is capable of binding to both active and non-active sites of ACE and its substrate HHL complex, thus reducing the catalytic activity of ACE. RSRGVFF can be further utilized for research on lowering hypertension .
|
-
- HY-B0368
-
Captopril
Maximum Cited Publications
22 Publications Verification
SQ 14225
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
Cancer
|
|
Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM .
|
-
- HY-N4090R
-
|
|
Reference Standards
Angiotensin-converting Enzyme (ACE)
ERK
MMP
p38 MAPK
|
Cardiovascular Disease
|
|
Vicenin 3 (Standard) is the analytical standard of Vicenin 3. Vicenin 3 is an angiotensin-converting enzyme (ACE) inhibitor (IC50 = 46.91 μM) that can be isolated from the aerial parts of Desmodium styracifolium. Vicenin 3 ameliorates IL-1β-induced extracellular matrix degradation in SW1353 chondrocytes by regulating the MAPK pathway. Vicenin 3 can be used for the study of osteoarthritis (OA) and hypertension .
|
-
- HY-B0130R
-
|
S-9490 (Standard)
|
Angiotensin-converting Enzyme (ACE)
NF-κB
STAT
Sirtuin
Reference Standards
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
Perindopril (Standard) is the analytical standard of Perindopril. This product is intended for research and analytical applications. Perindopril (S-9490) is an orally available, long-acting angiotensin-converting enzyme (ACE) inhibitor. Perindopril inhibits inflammatory cell influx and intimal thickening, preserving elastin on the inside of the aorta. Perindopril effectively inhibits experimental abdominal aortic aneurysm (AAA) formation in a rat model and reduces pulmonary vasoconstriction in rats with pulmonary hypertension .
|
-
- HY-B0093AS
-
-
- HY-B0093AR
-
-
- HY-118472R
-
|
CGS 14831 (Standard)
|
Drug Metabolite
Reference Standards
Endogenous Metabolite
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Benazeprilat (Standard) is the analytical standard of Benazeprilat. This product is intended for research and analytical applications. Benazeprilat is an orally active and the active metabolite of benazepril, a carboxyl-containing ACE inhibitor with antihypertensive activity. Benazepril is a well-established antihypertensive agent, both in monoresearch and in combination with other classes of drugs including thiazide diuretics and calcium channel blockers. Benazepril is a first-line research in reducing various pathologies associated with CV risk and secondary end-organ damage .
|
-
- HY-B0368S
-
|
SQ 14225-d3
|
Isotope-Labeled Compounds
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Captopril-d3 is deuterium labeled Captopril. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM .
|
-
- HY-B0130S1
-
-
- HY-182445
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
FPL 66564 is a short-acting angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 5.7 nM against rabbit ACE. FPL 66564 inhibits ACE activity at the functional level and is hydrolyzed in human blood into inactive hydrophilic metabolites. FPL 66564 modulates angiotensin I-induced pressor responses in anesthetized rats, and its effects rapidly return to baseline after cessation of intravenous infusion. FPL 66564 can be used for research on cardiovascular regulation related to critical illness .
|
-
- HY-P4641
-
|
Trp-Phe
|
Angiotensin-converting Enzyme (ACE)
Endothelin Receptor
|
Cardiovascular Disease
|
|
H-Trp-Phe-OH (Trp-Phe) is an ACE inhibitor and endothelial function regulator, with an ACE IC50 of 0.318 mg/mL. H-Trp-Phe-OH increases nitric oxide concentration, reduces endothelin-1 (ET-1) levels, and reverses norepinephrine-mediated endothelial cell dysfunction. H-Trp-Phe-OH exhibits antihypertensive activity. H-Trp-Phe-OH can be used in studies related to hypertension and atherosclerosis .
|
-
- HY-N3103R
-
|
Ethyl (E)-p-hydroxycinnamate (Standard); Ethyl trans-4-hydroxycinnamate (Standard)
|
Reference Standards
Drug Metabolite
|
Inflammation/Immunology
|
|
Benazeprilat (Standard) is the analytical standard of Benazeprilat. This product is intended for research and analytical applications. Benazeprilat is an orally active and the active metabolite of benazepril, a carboxyl-containing ACE inhibitor with antihypertensive activity. Benazepril is a well-established antihypertensive agent, both in monoresearch and in combination with other classes of drugs including thiazide diuretics and calcium channel blockers. Benazepril is a first-line research in reducing various pathologies associated with CV risk and secondary end-organ damage .
|
-
- HY-B0368R
-
|
SQ 14225 (Standard)
|
Reference Standards
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
Cancer
|
|
Captopril (Standard) is the analytical standard of Captopril. This product is intended for research and analytical applications. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM .
|
-
- HY-133829
-
|
|
Angiotensin-converting Enzyme (ACE)
NO Synthase
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
|
|
Zofenoprilat is an angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 1.7 nM. Zofenoprilat exerts cardioprotective and renoprotective effects by inhibiting angiotensin II expression and lowering blood pressure. Zofenoprilat promotes NO production and reduces endothelin-1 (ET-1) expression. Zofenoprilat decreases TNFα-induced ROS production and protects vascular endothelial function. Zofenoprilat regulates oxidative stress-related molecules and possesses antioxidant activity. Zofenoprilat can be used in studies related to hypertension and congestive heart failure .
|
-
- HY-105572
-
|
MC-838 calcium
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Moveltipril calcium (MC-838 calcium) is an orally active angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Moveltipril calcium binds via a stable thioester bond and exhibits relative resistance to enzymatic hydrolysis in rat liver homogenate. Moveltipril calcium effectively inhibits ACE extracted from rabbit lung in a concentration-dependent manner. Moveltipril calcium is able to highly specifically inhibit the contractile response to angiotensin-I (AI) in free rat aortic rings and guinea pig ileum preparations, while enhancing the contractile response to calcitonin .
|
-
- HY-165277
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
ε-Biotinamidocaproyl-β-alanyl-β-alanyl-lisinopril is an angiotensin-converting enzyme (ACE) inhibitor. Structurally, ε-Biotinamidocaproyl-β-alanyl-β-alanyl-lisinopril is a biotinylated derivative of lisinopril (HY-18206), with a chemical structure linking the biotin molecule and the lisinopril molecule composed of 19 atoms. ε-Biotinamidocaproyl-β-alanyl-β-alanyl-lisinopril can bind to both ACE and streptavidin (HY-P3152) simultaneously, making it possible to separate and purify ACE using streptavidin-agarose beads .
|
-
- HY-B0368S1
-
|
SQ 14225-13C5,15N
|
Isotope-Labeled Compounds
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
Cancer
|
|
Captopril- 13C5, 15N (SQ 14225- 13C5, 15N) is 13C and 15N labeled Captopril. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM .
|
-
- HY-126404
-
|
|
Environmental Pollutants
Interleukin Related
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Casein hydrolysate is an orally effective, multi-functional mixture of bioactive peptides, a hydrolysis product of casein (HY-125865), containing ACE inhibitors and immunomodulatory target regulators, among others. Casein hydrolysate releases short-chain bioactive peptides through enzymatic hydrolysis of casein, increasing cellular glutathione and catalase levels, enhancing ConA-induced IL-2 production, and exhibiting metal ion chelation, free radical scavenging, antibacterial, and mineral absorption-promoting effects. Casein hydrolysate lowers blood pressure by inhibiting angiotensin-converting enzyme (ACE) and reducing bradykinin degradation .
|
-
- HY-W010991
-
|
FAPGG
|
Angiotensin-converting Enzyme (ACE)
|
Others
|
|
N-[3-(2-Furyl)acryloyl]-Phe-Gly-Gly (FAPGG) is a specific substrate of angiotensin converting enzyme (ACE) with a Ki of 2.546×10 -4 M. It is used as a chromogenic probe for quantitative detection of ACE activity. N-[3-(2-Furyl)acryloyl]-Phe-Gly-Gly can be hydrolyzed by ACE to generate N-[3-(2-furyl)acryloyl]-Phe (FAP) and Gly-Gly, and the ACE inhibitory effect is monitored by photometry. FAPGG competitively binds to the active center of ACE and is a key tool for screening ACE inhibitors such as Captopril (HY-B0368) and Dioscorin. Its reversible mechanism of action supports hypertension research and drug development targeting the renin-angiotensin system .
|
-
![N-[3-(2-Furyl)acryloyl]-Phe-Gly-Gly](//file.medchemexpress.com/product_pic/hy-w010991.gif)
- HY-105111
-
|
|
Parasite
Angiotensin-converting Enzyme (ACE)
HSV
DNA/RNA Synthesis
|
Cardiovascular Disease
Metabolic Disease
|
|
P-536 is a ACE inhibitor that also inhibits herpes simplex virus HSV-1 thymidine kinase and Trypanosoma cruzi RNA polymerase. By inhibiting the renin-angiotensin system, downregulating the expression of AT1R and NOX4, and reducing oxidative stress (decreasing plasma hydrogen peroxide (H2O2) and 8-isoprostaglandin levels), P-536 effectively reduces systolic blood pressure and improves vascular reactivity. P-536 also inhibits the replication of DNA/RNA viruses such as HSV-1 by blocking nucleotide metabolism and nucleic acid synthesis, competitively inhibits RNA synthesis in Trypanosoma cruzi, and inhibits amastigote replication, thereby impeding its growth. P-536 is suitable for research on hypertension, insulin resistance, and Chagas disease .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-W010991
-
|
FAPGG
|
Fluorescent Dyes
|
|
N-[3-(2-Furyl)acryloyl]-Phe-Gly-Gly (FAPGG) is a specific substrate of angiotensin converting enzyme (ACE) with a Ki of 2.546×10 -4 M. It is used as a chromogenic probe for quantitative detection of ACE activity. N-[3-(2-Furyl)acryloyl]-Phe-Gly-Gly can be hydrolyzed by ACE to generate N-[3-(2-furyl)acryloyl]-Phe (FAP) and Gly-Gly, and the ACE inhibitory effect is monitored by photometry. FAPGG competitively binds to the active center of ACE and is a key tool for screening ACE inhibitors such as Captopril (HY-B0368) and Dioscorin. Its reversible mechanism of action supports hypertension research and drug development targeting the renin-angiotensin system .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-137875
-
|
N-Benzoyl-Gly-His-Leu hydrate
|
Angiotensin-converting Enzyme (ACE)
Amino Acid Derivatives
|
Cardiovascular Disease
|
|
Hippuryl-His-Leu-OH (N-Benzoyl-Gly-His-Leu) hydrate is a specific substrate for angiotensin-converting enzyme ACE I and is a molecular tool used for ACE activity detection in in vitro experiments. Hippuryl-His-Leu-OH hydrate is hydrolyzed by ACE through competitive binding. Under ACE catalysis, Hippuryl-His-Leu-OH hydrate undergoes hydrolysis to produce hippuric acid (HA). The amount of HA produced can be used to quantitatively assess ACE activity or screen for ACE inhibitors. The His-Leu released from Hippuryl-His-Leu-OH hydrate can also react with o-phthalaldehyde or Fluorescamine (HY-D0715) for fluorescence detection. Hippuryl-His-Leu-OH hydrate can be applied to the in vitro screening of ACE inhibitors for hypertension and cardiovascular diseases, and is also used in the study of changes in ACE activity during physiological and pathological processes such as renal compensatory hypertrophy .
|
-
- HY-W010991
-
|
FAPGG
|
Angiotensin-converting Enzyme (ACE)
|
Others
|
|
N-[3-(2-Furyl)acryloyl]-Phe-Gly-Gly (FAPGG) is a specific substrate of angiotensin converting enzyme (ACE) with a Ki of 2.546×10 -4 M. It is used as a chromogenic probe for quantitative detection of ACE activity. N-[3-(2-Furyl)acryloyl]-Phe-Gly-Gly can be hydrolyzed by ACE to generate N-[3-(2-furyl)acryloyl]-Phe (FAP) and Gly-Gly, and the ACE inhibitory effect is monitored by photometry. FAPGG competitively binds to the active center of ACE and is a key tool for screening ACE inhibitors such as Captopril (HY-B0368) and Dioscorin. Its reversible mechanism of action supports hypertension research and drug development targeting the renin-angiotensin system .
|
-
- HY-P3985
-
|
Bradykinin potentiating peptide B
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
Others
|
|
Bradykinin potentiator B (Bradykinin potentiating peptide B) is venom of Agkistrodon halys blomhoffi. Bradykinin potentiator B is a potent ACE inhibitor. Bradykinin potentiator inhibits the activity of bradykinin inhibitory peptidase .
|
-
- HY-P4641
-
|
Trp-Phe
|
Angiotensin-converting Enzyme (ACE)
Endothelin Receptor
|
Cardiovascular Disease
|
|
H-Trp-Phe-OH (Trp-Phe) is an ACE inhibitor and endothelial function regulator, with an ACE IC50 of 0.318 mg/mL. H-Trp-Phe-OH increases nitric oxide concentration, reduces endothelin-1 (ET-1) levels, and reverses norepinephrine-mediated endothelial cell dysfunction. H-Trp-Phe-OH exhibits antihypertensive activity. H-Trp-Phe-OH can be used in studies related to hypertension and atherosclerosis .
|
-
- HY-P11300
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
YKYY, a antihypertensive peptide, is an Angiotensin I-converting enzyme (ACE) inhibitor with an IC50 of 64.2 μM. YKYY can be isolated for the peptic digest of wakame Undaria pinnatifida. YKYY can be used for hypertension research .
|
-
- HY-P11300A
-
-
- HY-P3991
-
-
- HY-P4257
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
L-Isoleucyl-L-arginine is a dipeptide formed from L-isoleucine and L-arginine residues. L-Isoleucyl-L-arginine is a potent angiotensin-converting enzyme (ACE) inhibitor. L-Isoleucyl-L-arginine can be used for research of hypertension .
|
-
- HY-P4551
-
|
N-Benzoyl-Gly-His-Leu
|
Angiotensin-converting Enzyme (ACE)
Amino Acid Derivatives
|
Cardiovascular Disease
|
|
Hippuryl-His-Leu-OH (N-Benzoyl-Gly-His-Leu) is a specific substrate for angiotensin-converting enzyme (ACE I) and a molecular tool used for ACE activity detection in in vitro experiments. Hippuryl-His-Leu-OH is hydrolyzed by ACE through competitive binding. Under ACE catalysis, Hippuryl-His-Leu-OH undergoes hydrolysis to produce hippuric acid (HA). The amount of HA produced can be used to quantitatively assess ACE activity or screen for ACE inhibitors. The released His-Leu can also react with o-phthalaldehyde or Fluorescamine (HY-D0715) for fluorescence detection. Hippuryl-His-Leu-OH can be applied to the in vitro screening of ACE inhibitors for hypertension and cardiovascular diseases, and is also used in the study of ACE activity changes in physiological and pathological processes such as renal compensatory hypertrophy .
|
-
- HY-P3976
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Lactalbumin B (50-53) Alpha [Lactorphin Alpha], bovine is a blood pressure lowering peptide containing 4 amino acids. Lactalbumin B (50-53) Alpha [Lactorphin Alpha], bovine is an angiotensin-converting Enzyme (ACE) inhibitor. Lactalbumin B (50-53) Alpha [Lactorphin Alpha], bovine can be used in research of high blood pressure .
|
-
- HY-P2366
-
-
- HY-P2227
-
-
- HY-W092110
-
-
- HY-P2619
-
-
- HY-P2605
-
-
- HY-P5774
-
-
- HY-P3424
-
-
- HY-P10808
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
RSRGVFF (FOXP3 inhibitor P60) is a mixed-type angiotensin-converting enzyme (ACE) inhibitor with blood-brain barrier permeability, boasting an IC50 value of 5.01 μM . RSRGVFF is capable of binding to both active and non-active sites of ACE and its substrate HHL complex, thus reducing the catalytic activity of ACE. RSRGVFF can be further utilized for research on lowering hypertension .
|
-
- HY-P11572
-
-
- HY-P11740
-
|
|
Angiotensin-converting Enzyme (ACE)
Drug Intermediate
|
Others
|
|
VYPFPGPIHN is a precursor peptide of β-casomorphin (HY-P0179) and also an ACE inhibitor (IC50 = 123 μM). VYPFPGPIHN resists hydrolysis by peptidases associated with intestinal cell monolayers, maintaining structural integrity and ACE inhibitory activity. VYPFPGPIHN is not extensively taken up or transported by differentiated intestinal cell monolayers .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0331AS
-
|
|
|
Enalapril-d5 (maleate) is deuterium labeled Enalapril, which is an angiotensin converting enzyme (ACE) inhibitor.
|
-
-
- HY-B0279S
-
|
|
|
Ramipril-d5 is the deuterium labeled Ramipril. Ramipril (HOE-498) is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 5 nM.
|
-
-
- HY-B0279S1
-
|
|
|
Ramipril-d3 is the deuterium labeled Ramipril . Ramipril (HOE-498) is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 5 nM.
|
-
-
- HY-A0115S1
-
|
|
|
Ramiprilat-d5 is deuterium labeled Ramiprilat. Ramiprilat (HOE 498 diacid), an active metabolite of Ramipril, is a potent and orally active angiotensin converting enzyme (ACE) inhibitor with a Ki value of 7 pM. Ramiprilat can be used for high blood pressure and heart failure research .
|
-
-
- HY-B0231BS
-
|
|
|
Enalaprilat-d5 (sodium) is the deuterium labeled Enalaprilat(MK-422), which is an angiotensin-converting enzyme (ACE) inhibitor.
|
-
-
- HY-A0116S
-
|
|
|
Trandolaprilate-d5 is a deuterium labeled Trandolaprilate (Trandolaprilat). Trandolaprilate is an angiotensin-converting enzyme (ACE) inhibitor .
|
-
-
- HY-B0231AS
-
|
|
|
Enalaprilat-d5 is the deuterium labeled Enalaprilat(MK-422), which is an angiotensin-converting enzyme (ACE) inhibitor.
|
-
-
- HY-108321S
-
|
|
|
Zofenopril-d5 is deuterium labeled Zofenopril. Zofenopril is an angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 81 μM.
|
-
-
- HY-107337S
-
|
|
|
Delapril-d3 (hydrochloride) is the deuterium labeled Delapril hydrochloride. Delapril hydrochloride is an angiotensin-converting enzyme (ACE) inhibitor for the treatment of cardiovascular diseases .
|
-
-
- HY-B0279S2
-
|
|
|
Ramipril-d4 is deuterated labeled Ramipril (HY-B0279). Ramipril (HOE-498) is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 5 nM.
|
-
-
- HY-B0592S
-
|
|
|
Trandolapril-d5 is a deuterium labeled Trandolapril (RU44570). Trandolapril is an orally active angiotensin converting enzyme (ACE) inhibitor for hypertension and congestive heart failure (CHF) .
|
-
-
- HY-117281S
-
|
|
|
Moexipril-d5 is the deuterium labeled Moexipril. Moexipril hydrochloride is a potent orally active non-sulfhydryl angiotensin converting enzyme(ACE) inhibitor, which is used for the treatment of hypertension and congestive heart failure .
|
-
-
- HY-109592S
-
|
|
|
Imidaprilate-d5 is deuterium labeled Imidaprilate. Imidaprilate is an active metabolite of TA-6366, acts as a potent angiotensin converting enzyme (ACE) inhibitor, with an IC50 of 2.6 nM, and is used in the research of hypertensive disease.
|
-
-
- HY-B0477AS1
-
|
|
|
Quinapril-d5 hydrochloride (CI-906-d5) is the deuterium labeled Quinapril hydrochloride. Quinapril hydrochloride (CI-906) is a prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications .
|
-
-
- HY-B0331S1
-
|
|
|
Enalapril-d3 (MK-421-d3) is deuterium labeled Enalapril. Enalapril (MK-421) is an angiotensin-converting enzyme (ACE) inhibitor, can be used for hypertensive diseases research .
|
-
-
- HY-A0043S2
-
|
|
|
Cilazapril-d5 (Ro 31-2848-d5) trifluoroacetate is the deuterium labeled Cilazapril (HY-A0043). Cilazapril is an angiotensin-converting enzyme (ACE) inhibitor used for the study of hypertension and congestive heart failure.
|
-
-
- HY-100713S
-
|
|
|
Temocapril-d5 is the deuterium labeled Temocapril. Temocapril is an angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .
|
-
-
- HY-B0130S
-
|
|
|
Perindopril-d4 t-butylamine salt is the deuterium labeled Perindopril t-butylamine salt. Perindopril t-butylamine salt is a long-acting ACE inhibitor of which is used to treat high blood pressure, heart failure or stable coronary artery disease .
|
-
-
- HY-W739949
-
|
|
|
Imidaprilat-d3 (6366A-d3) is deuterium labeled Imidaprilate. Imidaprilate is an active metabolite of TA-6366, acts as a potent angiotensin converting enzyme (ACE) inhibitor, with an IC50 of 2.6 nM, and is used in the research of hypertensive disease .
|
-
-
- HY-A0116S1
-
|
|
|
Trandolaprilate-d6 is the deuterium labeled Trandolaprilate . Trandolaprilate is a potent angiotensin-converting enzyme (ACE) inhibitor. Trandolaprilate partially inhibits angiotensin-I-mediated c-fos induction. Trandolaprilate is main bioactive metabolite of Trandolapril. Trandolaprilate shows high lipophilicity .
|
-
-
- HY-B1433S
-
|
|
|
Perindoprilat-d3 disodium is deuterated labeled Perindoprilat (HY-B1433). Perindoprilat (S 9780) is an angiotensin-converting enzyme (ACE) inhibitor with the IC50 value ranging from 1.5 to 3.2 nM. Perindoprilat can be used in hypertension research .
|
-
-
- HY-A0115S2
-
|
|
|
Ramiprilat-d4 hydrochloride is deuterated labeled Ramiprilat (HY-A0115). Ramiprilat (HOE 498 diacid), an active metabolite of Ramipril, is a potent and orally active angiotensin converting enzyme (ACE) inhibitor with a Ki value of 7 pM. Ramiprilat can be used for high blood pressure and heart failure research .
|
-
-
- HY-127026S
-
|
|
|
Quinaprilat-d5 is a deuterium-labeled Quinaprilat (HY-127026). Quinaprilat is a nonsulfhydryl ACE inhibitor, the active diacid metabolite of Quinapril. Quinaprilat specifically blocks the conversion of angiotensin I to the vasoconstrictor angiotensin II and inhibits bradykinin degradation. Quinaprilat primarily acts as a vasodilator, decreasing total peripheral and renal vascular resistance .
|
-
-
- HY-W744298
-
|
|
|
Trandolapril-d3 is the deuterium labeled Trandolapril (HY-B0592). Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
|
-
-
- HY-B0690S
-
|
|
|
Fosinopril-d5 (SQ28555-d5 (free acid)) is deuterium labeled Fosinopril. Fosinopril (SQ28555 free acid) is the ester proagent of angiotensin-converting enzyme (ACE) inhibitor with an IC50 value of 0.18 μM. Fosinopril demonstrates a non-competitive inhibition effect on ACE activity with an Ki value of 1.675 μM .
|
-
-
- HY-B0592S2
-
|
|
|
rac-Trandolapril-d5 (rac-RU44570-d5) is deuterium labeled Trandolapril. Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
|
-
-
- HY-B0093AS
-
|
|
|
Benazepril-d5 hydrochloride is deuterium labeled Benazepril hydrochloride. Benazepril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril hydrochloride inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. In addition, Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria. Benazepril hydrochloride can be used in the study of hypertension, heart failure and diabetic nephropathy .
|
-
-
- HY-B0368S
-
|
|
|
Captopril-d3 is deuterium labeled Captopril. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM .
|
-
-
- HY-B0130S1
-
|
|
|
Perindopril-d5 (S-9490-d5) is deuterium labeled Perindopril. Perindopril (S-9490) is an orally available, long-acting angiotensin-converting enzyme (ACE) inhibitor. Perindopril inhibits inflammatory cell influx and intimal thickening, preserving elastin on the inside of the aorta. Perindopril effectively inhibits experimental abdominal aortic aneurysm (AAA) formation in a rat model and reduces pulmonary vasoconstriction in rats with pulmonary hypertension .
|
-
-
- HY-B0368S1
-
|
|
|
Captopril- 13C5, 15N (SQ 14225- 13C5, 15N) is 13C and 15N labeled Captopril. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
![Lactalbumin B (50-53) Alpha [Lactorphin Alpha], bovine](http://file.medchemexpress.com/product_pic/hy-p3976.gif)
![N-[3-(2-Furyl)acryloyl]-Phe-Gly-Gly](http://file.medchemexpress.com/product_pic/hy-w010991.gif)
